Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
1,927,347
-
Share change
-
-485,091
-
Total reported value
-
$7,608,315
-
Price per share
-
$3.95
-
Number of holders
-
35
-
Value change
-
-$1,941,997
-
Number of buys
-
13
-
Number of sells
-
8
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q2 2019
As of 30 Jun 2019,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
35 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,927,347 shares.
The largest 10 holders included
VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, SABBY MANAGEMENT, LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., GROUP ONE TRADING, L.P., SUSQUEHANNA INTERNATIONAL GROUP, LLP, WOLVERINE TRADING, LLC, ETF MANAGERS GROUP, LLC, and NORTHERN TRUST CORP.
This page lists
35
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.